Ayala Pharmaceuticals, Inc. (AYLA) Upgraded to Buy: Here's Why

This article was originally published on Nasdaq

Ayala Pharmaceuticals, Inc. (AYLA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates — one of the most powerful forces impacting stock prices.

Responses